caa a22 4500 477057063 CHVBK 20180405111349.0 cr unu---uuuuu 170330e19960501xx s 000 0 eng 10.1007/s002280050085 doi (NATIONALLICENCE)springer-10.1007/s002280050085 Efficacy and safety of spirapril, a new ace-inhibitor, in elderly hypertensive patients [Elektronische Daten] [I. Kantola, A. Terént, T. Honkanen, V. Järveläinen, K. Ekman, M. Kataja] Objective: To compare the safety, efficacy, tolerability and duration of the antihypertensive effect of an ACE-inhibitor spirapril 3 mg or 6 mg in elderly (≥ 60 y) hypertensive patients in a multicentre, observational, double-blind randomised study. Methods: After a four-week placebo period, 39 patients were randomised to six weeks of treatment with spirapril 3 mg and 47 patients with spirapril 6 mg. Results: In the sitting position the mean (SD) decrease in systolic blood pressure (SBP) was 12(15) mmHg (95% confidence interval 7 to 17 mmHg) and in dia- stolic blood pressure (DBP) 10(7) mmHg (8 to 12 mmHg) in the 3-mg group and 10(13) mmHg (6 to 14 mmHg) and 9(7) mmHg (7 to 11 mmHg), respectively, in the 6-mg group (P < 0.001 compared to placebo period in both groups). Spirapril 3mg and 6 mg produced DBP ≤ 90 mmHg or a fall ≥ 10 mmHg in 53% and 51% of the patients, respectively. DBP was ≤ 90 mmHg in 36% and SBP ≤ 160 mmHg in 67% of the patients taking 3 mg and in 26% and 63% of the patients taking 6 mg spirapril. The most commonly reported adverse effects were cough (13-17%), dizziness, headache and insomnia. A trend to a more frequent adverse effects was observed in patients receiving spirapril 6 mg. Spirapril was both cholesterol- and glucose-neutral. Conclusion: According to our study, spirapril 3mg seems to be a suitable starting dose for the treatment of hypertension in the elderly patients. Springer-Verlag Berlin Heidelberg, 1996 Key words Hypertension nationallicence Spirapril nationallicence ACE-inhibitor nationallicence elderly nationallicence Kantola I. Department of Medicine, Turku University Central Hospital, FIN-20520 Turku, Finland, FI aut Terént A. Department of Medicine, Uppsala University Hospital, Uppsala, Sweden, SE aut Honkanen T. Hämeentie Medical Center, Helsinki, Finland, FI aut Järveläinen V. Kuntoutusyhtymä-Rehab Group Oy, Turku, Finland, FI aut Ekman K. Sandoz Oy, Helsinki, Finland, FI aut Kataja M. National Public Health Institute, Helsinki, Finland, FI aut https://doi.org/10.1007/s002280050085 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050085 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kantola I. Department of Medicine, Turku University Central Hospital, FIN-20520 Turku, Finland, FI aut NATIONALLICENCE 700 1- Terént A. Department of Medicine, Uppsala University Hospital, Uppsala, Sweden, SE aut NATIONALLICENCE 700 1- Honkanen T. Hämeentie Medical Center, Helsinki, Finland, FI aut NATIONALLICENCE 700 1- Järveläinen V. Kuntoutusyhtymä-Rehab Group Oy, Turku, Finland, FI aut NATIONALLICENCE 700 1- Ekman K. Sandoz Oy, Helsinki, Finland, FI aut NATIONALLICENCE 700 1- Kataja M. National Public Health Institute, Helsinki, Finland, FI aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer